2022
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABooster
2021
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
Thura M, Ye Z, Al-Aidaroos A, Xiong Q, Ong J, Gupta A, Li J, Guo K, Ang K, Zeng Q. PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Communications Biology 2021, 4: 923. PMID: 34326464, PMCID: PMC8322210, DOI: 10.1038/s42003-021-02449-8.Peer-Reviewed Original ResearchConceptsTumor relapsePhase 2 clinical trialStem cell markers SOX2Cell markers SOX2Polyploid giant cancer cellsTumor removal surgeryStem-like cellsAdjuvant immunotherapyGiant cancer cellsPrimary tumorClinical trialsTumor removalCancer cell formationAnimal modelsRelapse tumorsSolid tumorsRelapseRemoval surgeryEmbryonic stem cell markers SOX2TumorsAntibody drugsCancer cellsExtensive DNA damageMetastasisCell survival